Day One Announces Sale of Priority Review Voucher for $108 Million

Core Viewpoint - Day One Biopharmaceuticals has successfully sold its Priority Review Voucher (PRV) for $108 million, enhancing its financial position as it continues to launch OJEMDA and invest in cancer treatment development [1][2]. Financial Impact - The sale of the PRV provides non-dilutive capital, strengthening the company's balance sheet [2]. - A portion of the proceeds, amounting to $8.1 million, will be allocated to Viracta Therapeutics to fulfill obligations related to a license agreement [4]. Regulatory Context - The PRV was awarded under the Rare Pediatric Disease Priority Review Voucher Program, which incentivizes the development of treatments for rare pediatric diseases [3]. Company Overview - Day One Biopharmaceuticals focuses on developing targeted therapies for pediatric cancer, addressing a significant unmet need in therapeutic development [5]. - The company collaborates with clinical oncologists, families, and scientists to advance its pipeline, which includes tovorafenib (OJEMDA™) and pimasertib [6].